+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 16Years +
All Genders
ID07160686

Apixaban to Prevent Blood Clots in Lung Cancer Patients Receiving Chemotherapy A Phase III Randomized, Double-Blind, Placebo-Controlled Trial

Led by University of Birmingham · Updated on 2026-09-28

1456

Participants Needed

8

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether apixaban, an oral anticoagulant tablet, can reduce blood clots in people with lung cancer who are receiving chemotherapy or similar systemic anticancer treatments. Venous thromboembolism VTE is a common and serious complication in lung cancer patients undergoing such therapies, leading to poorer quality of life, higher healthcare costs, and increased morbidity and mortality. Current standard care does not routinely use blood thinners for outpatients receiving systemic anticancer therapy, and this trial aims to address that gap. Participants will be randomly assigned to receive either apixaban 2.5 mg tablets or a matching placebo, taken twice daily by mouth for six months alongside their cancer treatments. This phase 3, multicenter, double-blind, placebo-controlled trial will compare these two groups to assess if apixaban reduces the rate of VTE. The trial includes a total of 1456 patients recruited over 36 months with a follow-up period of 6 months for primary outcome measurement. During the trial, participants will be asked to take the study medication as directed and complete diaries recording treatment adherence. They will also complete quality of life and health resource use questionnaires. Researchers will monitor for blood clots confirmed by objective testing, bleeding events, survival outcomes, and patient-reported quality of life over six months. Female participants who can become pregnant are required to use effective contraception during and shortly after treatment. The studys total duration, including setup and analysis, is planned for 60 months.

CONDITIONS

Brief Title

Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

Research Team

A

Ann Pope, PhD

S

Sophia Magwaro, BSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here